@entity2059 oral solution for the treatment of XXXX .

@entity1 @entity390 @entity3100 @entity14476 @entity2059
Twenty-seven @entity1 (12 @entity1 , 15 @entity1 , age range 3-11 years, weight range 10-40 kg) were treated with @entity2059 oral solution 10 mg/mL given as pulse therapy for @entity3100 . The dosage regimen was 3 mg/kg per day given once daily in a fasting state with each pulse lasting 1 week. The first two pulses were separated by a 2-week off-drug period, and the second and third pulses had a 3-week period without drug between them. For each @entity1 a second and third pulse were administered if there was clinical evidence of @entity3100 at the time-point when the next pulse was due. The overall severity of @entity3100 at pretherapy was classified as mild, moderate or severe with the aetiology being: Trichophyton tonsurans, 24 @entity1 ; T. violaceum, two @entity1 and @entity14476 , one @entity1 . In 19 evaluable @entity1 , 12 weeks after starting therapy, the numbers of pulses of @entity2059 oral solution required to produce complete cure were, according to the severity of disease, mild @entity3100 (one pulse: four @entity1 ; two pulses: five), moderate disease (one pulse: two @entity1 ; two pulses: two; three pulses: two), and severe disease (three pulses: three @entity1 ). One @entity1 with moderate severity @entity3100 was clinically clear after three pulses of therapy but mycological examination was positive. Seven @entity1 were lost to follow-up and one discontinued therapy because of @entity390 . @entity2059 oral solution 3 mg/kg per day was generally well tolerated. Three @entity1 developed gastrointestinal adverse effects which were considered to be minor or 'nuisance' effects. The data from this preliminary report need to be confirmed in a larger group of @entity1 . It remains to be seen whether @entity2059 oral solution will become a practical alternative to the antifungal agents available in a liquid preparation for the treatment of @entity3100 .
